Exelixis' future depends on trial outcomes and patent risks. Find out why EXEL stock is a "Sell" despite cabozantinib's ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation's largest independent providers of urology and related specialty services, is one of the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...